dalbavancin News
Most Popular dalbavancin Story
Pfizer withdraws dalbavancin app
Pfizer has withdrawn U.S. and European marketing applications for dalbavancin--a drug for complicated skin and skin structure infections in adults--following feedback from regulatory agencies. The Read more...
Latest Headlines
- September 9, 2008
- June 15, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
